Geoff Meacham, Citi analyst, joins ‘Fast Money’ to talk what the year ahead holds for competition in the obesity drug market.
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi’s Meacham
Related posts
-
DC Crime Crackdown Tests Federal Prosecutors
Bloomberg TelevisionSun, August 9, 2026 10:42pmURL:Embed:A Bloomberg Law investigation finds federal prosecutors dismissed or downgraded many... -
El-Sayed Win Fuels Democratic Identity Debate
Bloomberg TelevisionSun, August 9, 2026 10:42pmURL:Embed:Abdul El-Sayed’s narrow Michigan Senate primary victory intensifies the debate over... -
Premium auto sales down as consumers shift to mainstream models
CNBC TelevisionSun, August 9, 2026 10:42pmURL:Embed:CNBC’s Phil LeBeau joins “Squawk Box” with new data on changing...